Todos strikes distribution partnership with OHC for GeneFinder COVID-19 Plus RealAMP Kit in US

Todos Medical Ltd (OTCQB:TOMDF) revealed Tuesday that it has struck a distribution partnership with South Korea’s Osang Healthcare Company (OHC) to distribute the GeneFinder COVID-19 Plus RealAMP Kit in the US. Founded in Rehovot, Israel with offices in New York City, Todos aims to make GeneFinder Plus “the primary kit” used for distribution in its fully automated COVID-19 PCR testing lab solutions. GeneFinder Plus has been granted emergency use authorization (EUA) by the US Food and Drug Administration (FDA), said the company. READ: Todos Medical completes automation equipment installation and training for its Brooklyn lab client “We are very pleased to enter into this partnership with OHC surrounding the distribution of GeneFinder Plus, one of the most sensitive kits to have received EUA from the FDA,” said Todos CEO Gerald Commissiong. “As PCR testing becomes more ingrained as the country re-opens, the emergence of new SARS-CoV-2 variants makes regulatory oversight of reagents that much more critical in the CLIA laboratory testing space.” Todos plans to work with OHC to expand the use of GeneFinder Plus to include saliva testing. Meanwhile, Jorge Leon, who is the chief medical officer for Oncology and Infectious Diseases at Todos, said data shows that GeneFinder Plus has an “exquisite lower limit of detection (LOD),” suggesting it is able to identify SARS-CoV-2 at “the very earliest stages of infection.” “As PCR testing in the US moves towards a standard serial testing paradigm in school, offices, sporting leagues and other areas of society preparing to re-open, it will be more critical that highly sensitive tests are used in order to identify infection early, and thus limit the spread,” added Leon. “The LOD of GeneFinder Plus, and its ability to identify infection with all the known variants currently circulating in the US, makes it well suited to promote as part of our offering tailored towards schools.” OHC's test is designed to detect SARS-CoV-2 through a gene-based reverse transcription reaction and real-time polymerase chain reaction (RT-PCR) testing process and can provide 384 test results per PCR machine in just over two hours. Todos has been granted sales and distribution rights to OHC’s product in the US and plans to leverage its customer base of labs performing high capacity COVID testing. "We are delighted with the Todos distribution partnership, especially now that we have established manufacturing in the US," said Osang Healthcare CEO Dong-Hyun Lee. "We will be able to deliver GeneFinder Plus kits anywhere in the US within 48 hours of ordering, a critical component to the ‘just in time’ supply chain many labs need to manage the cold chain requirements of PCR testing." Contact the author Uttara Choudhury at uttara@proactiveinvestors.com Follow her on Twitter: @UttaraProactive